- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00442208
An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers
April 21, 2008 updated by: POZEN
Primary: To compare the pharmacodynamic efficacy of PN 200 in controlling intragastric pH (percent time pH> 4.0) following twice daily administration at different dosing times relative to food (30 or 60 minutes prior to food or taken togeterh with food) on Day 5.
Study Overview
Detailed Description
This study is designed to evaluate the effect of different dosing times of PN 200 relative to food on the intragastric pH profile of PN 200.
PN 200 contains immediate release omeprazole, which may be subject to acid degradation in the stomach.
Food is known to have a buffering effect on acid and therefore may result in less degradation of immediate release omeprazole.
Alternatively, food may decrease the absorption of omeprazole in the duodenum.
The relative magnitude of these effects is unknown.
The data from this study will aid in choosing the optimal timing of PN dosing relative to food in future studies.
The study is not blinded because the primary endpoint (intragastric pH) is a physiological variable not believed to be readily influenced by conscious or subconscious subject control.
Study Type
Interventional
Enrollment
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27517
- Pozen Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or non-lactating, non-pregnant female subjects who are 18-55 years of age
Female subjects are eligible for participation in the study if they are of:
- Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,
Childbearing potential, have a negative pregnancy test (urine) at screening, and at least one of the following applies or is agreed to by the subject:
- Female sterilization or sterilization of male partner; or,
- Hormonal contraception by oral route, implant, injectable, vaginal ring; or,
- Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year;
- Double barrier method (2 physical barriers or 1 physical barrier plus spermicide); or
- Any other method with published data showing that the lowest expected failure rate is less than 1% per year
- Physical examination findings within normal limits for age
- Able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed
Exclusion Criteria:
- History of hypersensitivity, allergy or intolerance to omeprazole or other proton-pump inhibitors
- History of hypersensitivity, allergy or intolerance to any NSAID (including aspirin) and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps
- History of peptic ulcer disease or other acid related gastrointestinal symptoms
- Participation in any study of an investigational treatment in the 4 weeks before screening or participation in another study at any time during the period of this study
- Any significant medical illness that would contraindicate participation in the study
- Gastrointestinal disorder or surgery leading to impaired drug absorption
- Any significant mental illness, such as schizophrenia or bipolar disorder
- Cardio- or cerebrovascular disease, based on history or risk factors, or clinically significant ECG in the investigator's opinion
- Personal or family history of an inherited or acquired bleeding disorder
- Positive test result for H pylori at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To compare the pharmacodynamic efficacy of PN 200 in controlling intragastric pH (percent time pH > 4.0)
|
Secondary Outcome Measures
Outcome Measure |
---|
To evaluate the effect of different dosing times of PN 200 on the pharmacokinetic properties of omeprazole
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
February 1, 2008
Study Completion (Actual)
February 1, 2008
Study Registration Dates
First Submitted
February 28, 2007
First Submitted That Met QC Criteria
February 28, 2007
First Posted (Estimate)
March 1, 2007
Study Record Updates
Last Update Posted (Estimate)
April 22, 2008
Last Update Submitted That Met QC Criteria
April 21, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PN200-105
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on PN 200
-
The University of Texas Health Science Center at...Susan G. Komen Breast Cancer FoundationCompleted
-
The University of Texas Health Science Center at...National Cancer Institute (NCI)CompletedBreast Cancer | Colorectal Cancer | Prostate CancerUnited States
-
PfizerCompletedNeoplasms | Multiple Myeloma | Lymphoma, Malignant | ThrombocytopeniaUnited States, Argentina, Mexico
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompletedPlaque PsoriasisUnited States, Canada, Germany, France, Spain, Poland
-
Columbia UniversityNational Institute on Drug Abuse (NIDA)CompletedSexual Behavior | Substance AbuseUnited States
-
PfizerCompletedSarcomaUnited States
-
PluroGen Therapeutics, IncArkios BioDevelopment InternationalCompletedDiabetic Foot Ulcer | InfectionUnited States
-
Johns Hopkins UniversityNational Institute of Nursing Research (NINR)Active, not recruitingPelvic Inflammatory DiseaseUnited States
-
NYU Langone HealthCenters for Disease Control and PreventionRecruitingCancer ScreeningUnited States